Business

Biocon Biologics Inks Out-Licensing Agreement With Yoshindo Inc.

October 17, 202245 views0

[ad_1]

Under the terms of this deal, Japan-based Yoshindo gets exclusive commercialisation rights in Japan for Ustekinumab and Denosumab.

[ad_2]

Source link

What is your reaction?

Excited

Happy

In Love

Not Sure

Silly

Comments are closed.

More in:Business

Business

Elon Musk’s Twitter Is Shakespearean Psychodrama Set In Silicon Valley

[ad_1] (Bloomberg Businessweek) — It was Day 5 of Elon Musk’s riveting, rambunctious takeover of ...

December 17, 2022

Business

CLSA Expects Life Insurance Sector To Outperform In 2023

[ad_1] CLSA has initiated a ‘buy’ rating on all four listed private life insurers and ...

December 17, 2022

Business

Goldman Weighs Up To 4,000 Job Cuts In Potential 8% Pullback

[ad_1] Goldman Sachs Group Inc. may eliminate as many as 4,000 employees, according to a ...

December 16, 2022

Now Reading

Biocon Biologics Inks Out-Licensing Agreement With Yoshindo Inc.

1min read

0 %

Biocon Biologics Inks Out-Licensing Agreement With Yoshindo Inc.

What is your reaction?

Markets trade flat but Quant posts impressive 23% gain

Rip That Original, Time For Remakes To R.I.P?

More in:Business

Elon Musk’s Twitter Is Shakespearean Psychodrama Set In Silicon Valley

CLSA Expects Life Insurance Sector To Outperform In 2023

Goldman Weighs Up To 4,000 Job Cuts In Potential 8% Pullback

Posts List

Required characteristics of an ideal web service provider

How can I maximize my potential winnings from the greatest internet gambling bonuses?

Useful Tips to Know While Transporting a Car

UAN Registration: Knowing the Pros and Cons

SEBI Comes Out With Framework For Orderly Winding Down Of Clearing Corps

Recent Posts

Archives

Share

What is your reaction?

You may also like

More in:Business

Posts List

Recent Posts

Archives

Latest Posts